Zeria Pharmaceutical Co., Ltd.
4559.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | 0.48 | 0.27 | 0.76 |
| FCF Yield | 11.55% | 8.84% | 10.59% | 8.76% |
| EV / EBITDA | 5.68 | 6.83 | 9.62 | 11.06 |
| Quality | ||||
| ROIC | 6.93% | 5.86% | 6.27% | 3.88% |
| Gross Margin | 73.25% | 66.27% | 72.37% | 70.80% |
| Cash Conversion Ratio | 1.30 | 1.58 | 1.81 | 1.56 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.49% | 8.35% | 9.03% | -0.50% |
| Free Cash Flow Growth | 38.72% | -21.09% | 39.43% | 181.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.85 | 1.48 | 2.41 | 3.54 |
| Interest Coverage | 26.97 | 21.22 | 26.73 | 20.18 |
| Efficiency | ||||
| Inventory Turnover | 1.42 | 1.76 | 1.48 | 1.45 |
| Cash Conversion Cycle | 306.04 | 261.87 | 300.99 | 306.91 |